Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 3/2006

01-03-2006 | Article

The effect of sensitisation to insulin with pioglitazone on fasting and postprandial lipid metabolism, lipoprotein modification by lipases, and lipid transfer activities in type 2 diabetic patients

Authors: K. Al Majali, M. B. Cooper, B. Staels, G. Luc, M-R. Taskinen, D. J. Betteridge

Published in: Diabetologia | Issue 3/2006

Login to get access

Abstract

Aims/hypothesis

Insulin resistance is thought to be central to the pathogenesis of diabetic dyslipidaemia. We hypothesised that improving insulin sensitivity would improve fasting and postprandial triglyceride metabolism in patients with type 2 diabetes. To this aim we studied fasting and postprandial lipaemia in type 2 diabetic patients before and after sensitisation to insulin with pioglitazone, compared with that observed in patients on an insulin-providing regime.

Methods

In a double-blind placebo-controlled protocol, 22 patients with type 2 diabetes were randomly allocated to receive either pioglitazone (45 mg/day) or glibenclamide (5 mg/day), for a 20-week period. Fasting and postprandial lipid metabolism were investigated at baseline and at the end of the treatment period. A group of non-diabetic subjects was also studied.

Results

Compared with glibenclamide treatment, pioglitazone treatment decreased fasting triglyceride, glucose and insulin levels and the homeostasis model assessment score of insulin resistance. Decreased fasting triglyceride after pioglitazone treatment was due to reduced VLDL triglyceride, particularly VLDL-2. Lipoprotein lipase activity was unchanged by pioglitazone treatment but hepatic lipase showed a significant decrease. Pioglitazone treatment lowered total postprandial triglyceride, as well as chylomicron- and chylomicron-remnant retinyl palmitate levels to normal. Glucose disposal improved but remained abnormal.

Conclusions/interpretation

Insulin sensitisation with pioglitazone has major effects in restoring postprandial lipaemia to normal, while also correcting fasting hypertriglyceridaemia; both factors may have consequences for atherogenic risk in diabetes.
Literature
1.
Krentz AJ (2003) Lipoprotein abnormalities and their consequences for patients with type diabetes. Diabetes Obes Metab 5 (Suppl 1):S19–S27CrossRefPubMed
2.
Duvillard L, Pont F, Florentin E, Galland-Jos C, Gambert P, Verges B (2000) Metabolic abnormalities of apolipoprotein B-containing lipoproteins in non-insulin-dependent diabetes: a stable isotope kinetic study. Eur J Clin Invest 30:685–694CrossRefPubMed
3.
Koba S, Hirano T, Murayama S et al (2003) Small dense LDL phenotype is associated with postprandial increases of large VLDL and remnant-like particles in patients with acute myocardial infarction. Atherosclerosis 170:131–140CrossRefPubMed
4.
Cooper MB, Tan KC, Hales CN, Betteridge DJ (1996) Postprandial lipid metabolism and beta-cell function in non-insulin-dependent (type 2 diabetes mellitus) after a mixed meal with a high fat content. Diabet Med 13:816–827CrossRefPubMed
5.
Mero N, Syvanne M, Taskinen M-R (1998) Postprandial lipid metabolism in diabetes. Atherosclerosis 141 (Suppl 1):S53–S55CrossRefPubMed
6.
van Wijk JP, Halkes CJ, Erkelens DW, Castro-Cabezas M (2003) Fasting and daylong triglycerides in obesity with and without type 2 diabetes. Metabolism 52:1043–1049CrossRefPubMed
7.
Brunzell JD, Hazzard WR, Porte D Jr, Bierman EL (1973) Evidence for a common saturable triglyceride removal mechanism for chylomicrons and very low density lipoproteins in man. J Clin Invest 52:1578–1585PubMedCrossRef
8.
Riemens S, van-Tol A, Sluiter W, Dullaart R (1998) Elevated plasma cholesteryl ester transfer in NIDDM: relationships with apolipoprotein B-containing lipoproteins and phospholipid transfer protein. Atherosclerosis 140:71–79CrossRefPubMed
9.
10.
Reaven GM (2002) Multiple CHD risk factors in type 2 diabetes: beyond hyperglycaemia. Diabetes Obes Metab 4 (Suppl 1):S13–S18CrossRefPubMed
11.
Lebovitz HE, Banerji MA (2001) Insulin resistance and its treatment by thiazolidinediones. Recent Prog Horm Res 56:265–294CrossRefPubMed
12.
Olefsky JM, Saltiel AR (2000) PPARγ and the treatment of insulin resistance. Trends Endocrinol Metab 11:362–368CrossRefPubMed
13.
Desvergne B, Wahli W (1999) Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 20:649–688CrossRefPubMed
14.
Fischer S, Patzak A, Rietzsch H et al (2003) Influence of treatment with acarbose or glibenclamide on insulin sensitivity in type 2 diabetic patients. Diabetes Obes Metab 5:38–44CrossRefPubMed
15.
Vakkilainen J, Mero N, Schweizer A, Foley JE, Taskinen MR (2002) Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes. Diabetes Metab Res Rev 18:484–490CrossRefPubMed
16.
Fletcher CD, Barnes JF, Farish E (1994) A rapid semi-micro method for the separation of lipoprotein fractions that uses a benchtop ultracentrifuge. Clin Chim Acta 226:95–99CrossRefPubMed
17.
Cathcart S, Dominiczak MH (1990) The measurement of lipoprotein subfractions in plasma using a tabletop ultracentrifuge. Ann Clin Biochem 27:459–464PubMed
18.
Leonhardt W, Pietzsch J, Nitzsche S (1994) Very-fast ultracentrifugation of human plasma lipoproteins: influence of the centrifugal field on lipoprotein composition. Clin Chim Acta 224:21–32CrossRefPubMed
19.
Mackness MI, Durrington PN (1992) Lipoprotein separation and analysis for clinical studies. In: Converse CA, Skinner ER (eds) Lipoprotein analysis—a practical approach. IRL, Oxford, pp 1–42
20.
Demacker PN, Hijmans AG, Vos-Janssen HE, van’t-Laar A, Jansen AP (1980) A study of the use of polyethylene glycol in estimating cholesterol in high-density lipoprotein. Clin Chem 26:1775–1779PubMed
21.
De Ruyter MG, De Leenheer AP (1978) Simultaneous determination of retinol and retinyl esters in serum or plasma by reversed-phase high-performance liquid chromatography. Clin Chem 24:1920–1923PubMed
22.
Tan KCB, Cooper MB, Ling KLE et al (1995) Fasting and postprandial determinants for the occurrence of small dense LDL species in non-insulin-dependent diabetic patients with or without hypertriglyceridaemia. Atherosclerosis 113:273–287CrossRefPubMed
23.
Bouly M, Masson D, Gross B et al (2001) Induction of the phospholipid transfer protein gene accounts for the high density lipoprotein enlargement in mice treated with fenofibrate. J Biol Chem 276:25841–25847CrossRefPubMed
24.
Henderson AD, Richmond W, Elkeles RS (1993) Hepatic and lipoprotein lipases selectively assayed in postheparin plasma. Clin Chem 39:218–223PubMed
25.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419CrossRefPubMed
26.
Dobiasova M, Frolich J (2001) The plasma parameter log(TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FERHDL). Clin Biochem 34:583–588CrossRefPubMed
27.
Bland JM, Altman DG (1996) Transformations means and confidence intervals. Br Med J 312:1079–1080
28.
Brown AM, Gibbons GF (2001) Insulin inhibits the maturation phase of VLDL assembly via a phosphoinositide 3-kinase-mediated event. Arterioscler Thromb Vasc Biol 21:1656–1661PubMedCrossRef
29.
Carpentier A, Taghibiglou C, Leung N et al (2002) Ameliorated hepatic insulin resistance is associated with normalization of microsomal triglyceride transfer protein expression and reduction in very low density lipoprotein assembly and secretion in the fructose-fed hamster. J Biol Chem 277:28795–28802CrossRefPubMed
30.
Frayn KN (2003) The glucose–fatty acid cycle: a physiological perspective. Biochem Soc Trans 31:1115–1119PubMed
31.
Michael MD, Kulkarni RN, Postic C et al (2000) Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol Cell 6:87–97CrossRefPubMed
32.
Maeda N, Takahashi M, Funahashi T et al (2001) PPARγ ligands increase expression and plasma concentrations of adiponectin an adipose-derived protein. Diabetes 50:2094–2099PubMedCrossRef
33.
Krasinski SD, Cohn JS, Russel RM, Schaefer EJ (1990) Postprandial plasma vitamin A metabolism in humans: a reassessment of the use of plasma retinyl ester as marker for intestinally derived chylomicrons and their remnants. Metabolism 39:357–365CrossRefPubMed
34.
Leung N, Naples M, Uffelman K, Szeto L, Adeli K, Lewis GF (2004) Rosiglitazone improves intestinal lipoprotein in the fat-fed Syrian Golden hamster. Atherosclerosis 174:235–241PubMed
35.
Jong MC, Rensen PC, Dahlmans VE, van der Boom H, van Berkel TJ, Havekes LM (2001) Apolipoprotein C-III deficiency accelerates triglyceride hydrolysis by lipoprotein lipase in wild-type and apoE knockout mice. J Lipid Res 42:1578–1585PubMed
36.
Nagashima K, Lopez C, Donovan D et al (2005) Effects of the PPARγ agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus. J Clin Invest 115:1323–1332CrossRefPubMed
37.
Cohn JS, Patterson BW, Uffelman KD, Davignon J, Steiner G (2004) Rate of production of plasma and very-low-density lipoprotein (VLDL) apolipoprotein C-III is strongly related to the concentration and level of production of VLDL triglyceride in male subjects with different body weights and levels of insulin sensitivity. J Clin Endocrinol Metab 89:3949–3955CrossRefPubMed
38.
Jansen H, Verhoeven AJM, Sijbrands EJC (2002) Hepatic lipase: a pro- or anti-atherogenic protein? J Lipid Res 43:1352–1362CrossRefPubMed
39.
Tan MH, Johns D, Glazer NB (2004) Pioglitazone reduces atherogenic index of plasma in patients with type 2 diabetes. Clin Chem 50:1184–1188CrossRefPubMed
40.
Dullaart RP, van Tol A (2001) Short-term acipimox decreases the ability of plasma from type 2 diabetic patients and healthy subjects to stimulate cellular cholesterol efflux: a potentially adverse effect on reverse cholesterol transport. Diabet Med 18:509–513CrossRefPubMed
41.
Riemens SC, van Tol A, Sluiter WJ, Dullaart RP (1998) Plasma phospholipid transfer protein activity is related to insulin resistance: impaired acute lowering by insulin in obese type II diabetic patients. Diabetologia 41:929–934CrossRefPubMed
42.
Iris JAM, Jonkers IJ, Smelt A-H et al (2003) Decreased PLTP mass but elevated PLTP activity linked to insulin resistance in HTG: effects of bezafibrate therapy. J Lipid Res 44:1462–1469CrossRefPubMed
43.
Riemens SC, van-Tol A, Sluiter WJ, Dullaart RP (1999) Plasma phospholipid transfer protein activity is lowered by 24-h insulin and acipimox administration: blunted response to insulin in type 2 diabetic patients. Diabetes 48:1631–1637PubMedCrossRef
44.
Van Harmelen V, Reynisdottir S, Cianflone K et al (1999) Mechanisms involved in the regulation of free fatty acid release from isolated human fat cells by acylation-stimulating protein and insulin. J Biol Chem 274:18243–18251CrossRefPubMed
45.
Tordjman J, Chauvet G, Quette J, Beale EG, Forest C, Antoine B (2003) Thiazolidinediones block fatty acid release by inducing glyceroneogenesis in fat cells. J Biol Chem 278:18785–18790CrossRefPubMed
46.
van Wijk JPH, de Koning EJP, Cabezas MC, Rabelink TJ (2005) Rosiglitazone improves postprandial triglyceride and FFA metabolism. Diabetes Care 28:844–849PubMedCrossRef
47.
Sakamoto J, Kimura H, Moriyama S et al (2000) Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochem Biophys Res Commun 278:704–711CrossRefPubMed
48.
Tan GD, Fielding BA, Currie JM et al (2005) The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes. Diabetologia 48:83–95PubMedCrossRef
49.
Narce M, Poisson J-P (2003) Novel PPARγ-dependent and independent effects for thiazolidinediones. Curr Opin Lipidol 14:651–652CrossRefPubMed
50.
Akbiyik F, Ray DM, Gettings KF, Blumberg N, Francis CW, Phipps RP (2004) Human bone marrow megakaryocytes and platelets express PPARγ, and PPARγ agonists blunt platelet release of CD40 ligand and thromboxanes. Blood 104:1361–1368CrossRefPubMed
Metadata
Title
The effect of sensitisation to insulin with pioglitazone on fasting and postprandial lipid metabolism, lipoprotein modification by lipases, and lipid transfer activities in type 2 diabetic patients
Authors
K. Al Majali
M. B. Cooper
B. Staels
G. Luc
M-R. Taskinen
D. J. Betteridge
Publication date
01-03-2006
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 3/2006
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-005-0092-4

Other articles of this Issue 3/2006

Diabetologia 3/2006 Go to the issue

Article

Evidence that oestrogen receptor-α plays an important role in the regulation of glucose homeostasis in mice: insulin sensitivity in the liver

Letter

Comment to: Patti ME, Mcmahon G, Mun EC et al. (2005) Severe hypoglycaemia post-gastric bypass requiring partial pancreatectomy: evidence for inappropriate insulin secretion and pancreatic islet hyperplasia. Diabetologia 48:2236–2240

Short communication

In treatment-naïve and antiretroviral-treated subjects with HIV, reduced plasma adiponectin is associated with a reduced fractional clearance rate of VLDL, IDL and LDL apolipoprotein B-100

Article

Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study

Review

Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review

Article

Cyclooxygenase-2 (PTGS2) inhibitors augment the rate of hexose transport in L6 myotubes in an insulin- and AMPKα-independent manner
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits